{"id":2127,"date":"2022-03-09T23:18:24","date_gmt":"2022-03-09T23:18:24","guid":{"rendered":"https:\/\/aisperu.org.pe\/?p=2127"},"modified":"2025-04-14T17:30:25","modified_gmt":"2025-04-14T17:30:25","slug":"america-latina-como-las-patentes-y-las-licencias-dificultan-el-acceso-a-los-tratamientos-del-covid-19","status":"publish","type":"post","link":"https:\/\/aisperu.org.pe\/cms\/america-latina-como-las-patentes-y-las-licencias-dificultan-el-acceso-a-los-tratamientos-del-covid-19\/","title":{"rendered":"Am\u00e9rica Latina: C\u00f3mo las patentes y las licencias dificultan el acceso a los tratamientos del COVID-19"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">EEUU, 09 de marzo de 2022, a casi dos a\u00f1os de la declaraci\u00f3n de la pandemia de COVID-19 que ha cobrado casi 6 millones de vidas, la inequidad para acceder a vacunas y tratamientos prometedores ha sido evidente dejando sin protecci\u00f3n a miles de ciudadanos. Am\u00e9rica Latina, no ha sido la excepci\u00f3n con resultados devastadores, a pesar de ello, los tratamientos recomendados por la OMS &nbsp;siguen siendo limitados para nuestros pa\u00edses por las barreras de patentes y acuerdos de licencia restrictivos, controlados por corporaciones farmac\u00e9uticas, &nbsp;nos referimos a los productos nirmatrelvir\/ritonavir y baricitinib<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">M\u00e1s informaci\u00f3n aqu\u00ed<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/msfaccess.org\/latin-america-how-patents-and-licensing-hinder-access-covid-19-treatments\">https:\/\/msfaccess.org\/latin-america-how-patents-and-licensing-hinder-access-covid-19-treatments<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>EEUU, 09 de marzo de 2022, a casi dos a\u00f1os de la declaraci\u00f3n de la pandemia de COVID-19 que ha cobrado casi 6 millones de vidas, la inequidad para acceder a vacunas y tratamientos prometedores ha sido evidente dejando sin protecci\u00f3n a miles de ciudadanos. Am\u00e9rica Latina, no ha sido la excepci\u00f3n con resultados devastadores, [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":2129,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_eb_attr":"","hide_page_title":"","footnotes":""},"categories":[7],"tags":[],"class_list":["post-2127","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias"],"_links":{"self":[{"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/posts\/2127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/comments?post=2127"}],"version-history":[{"count":1,"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/posts\/2127\/revisions"}],"predecessor-version":[{"id":5888,"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/posts\/2127\/revisions\/5888"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/media\/2129"}],"wp:attachment":[{"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/media?parent=2127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/categories?post=2127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aisperu.org.pe\/cms\/wp-json\/wp\/v2\/tags?post=2127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}